MASCT by Hengrui Yuanzheng Biotechnology for Soft Tissue Sarcoma: Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Soft Tissue Sarcoma.

Novel Computational tool helps analyze complex genetic regions

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today published a paper in Nature Methods, titled “Multiscale analysis

June 27, 2023

Newborn screening negatively effects short- and long-term health outcomes in infants with cystic fibrosis

The Journal of Pediatrics has published a manuscript by Stacey Martiniano, MD, pulmonary specialist at Children’s Hospital Colorado and associate professor of pediatrics at the

July 29, 2023

Applied Therapeutics gets FDA warning letter over study of rejected rare disease drug

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.